Business Context and Reporting Period
This Form 8-K filing by Rocket Pharmaceuticals, Inc. (RCKT) reports corporate governance changes effective September 24, 2025. The report was filed on September 23, 2025, and signed on September 29, 2025.
Key Financial Metrics
This filing does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not reported in this document.
Material Changes
- Board Departure: Dr. Gotham Makker resigned from the Board of Directors, effective September 24, 2025. The resignation was not due to any disagreement regarding the Company's operations, policies, or practices.
- Board Appointment: Dr. Peter Fong, President of RTW Investments LP, was appointed to the Board, effective September 24, 2025.
- Compensatory Arrangements: Upon appointment, Dr. Fong received two grants of Restricted Stock Units (RSUs):
- 30,000 RSUs vesting in equal monthly installments over three years.
- 23,333 RSUs vesting fully on the first anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No risks, contingencies, or unusual items were disclosed in this report. The Company confirmed there are no related person transactions or family relationships involving Dr. Fong and other directors or officers.
Investor Verification Checklist
- Verify the effective date of Dr. Makker's resignation and Dr. Fong's appointment (September 24, 2025).
- Confirm the vesting schedules for the 53,333 total RSUs granted to Dr. Fong.
- Review Dr. Fong's background and potential conflicts of interest as President of RTW Investments LP.
- Check subsequent filings for any impact on Board committee assignments or quorum.